期刊文献+

广东顺德1954~2013年麻风复发病例分析 被引量:2

RECURRENT CASES OF LEPROSY ANALYSIS OF GUANGDONG SHUNDE FROM 1954 TO 2013
下载PDF
导出
摘要 目的:研究广东顺德1954~2103年用氨苯砜单疗或联合化疗后麻风病患者的复发情况。方法对1954~2013年顺德开展麻风病防治工作较完整的麻风个案资料进行分析。结果1954~2013年间顺德累计复发患者64例,累计复发率为4.77%。平均治愈-复发间隔为(131.52±12.64)个月。多菌型的累计复发率高于少菌型的累计复发率(χ2=76.771, p<0.0001)。男女的复发率无统计学意义(χ2=2.349,p=0.125)。利福平600 mg+氧氟沙星400 mg联合化疗治愈患者的复发率为27.27%,高于其他联合化疗方案和氨苯砜单疗的复发率(χ2=7.974,p=0.034)。结论采用利福平和氧氟沙星联合化疗方案治愈的患者,其复发率远高于其他化疗方案,不建议继续使用和推广。麻风复发有长期危险性,长期监测随访,有助于发现复发患者。 Objective To study on leprosy relapse cases after DDS or MDT in Shunde City from 1954 to 1998. Methods The data of leprosy relapse cases in Shunde City from 1954 to 1998 were analyzed.Results There were a total of 64 leprosy relapse cases during 1954~1998 in Shunde City, and the relapse rate was 4.77%.The average of cure and Re-currence time were (131.52 ±12.64) months.The relapse rate of MB cases were higher than PB cases (χ2 =76.771, p〈0.000 1).The relapse rate for male and female were not statistical significance (χ2 =2.349, p=0.125).The relapse rate of Chemotherapy with RFP (600 mg) and OFLO (400 mg) was 27.27%.It was higher than other treatment plans (χ2=7.974,p=0.034).Conclusion The relapse rate of Chemotherapy with RFP and OFLO were higher than other kinds of treat-ment plans, and it not recommended again.Long-term follow-up can help us to find relapse cases.
出处 《现代医院》 2014年第8期19-20,共2页 Modern Hospitals
关键词 麻风 复发 利福平和氧氟沙星联合化疗方案 Leprosy Recurrence Chemotherapy with RFP and OFLO
  • 相关文献

参考文献6

  • 1李文英,安茂义.57例麻风复发情况分析[C].麻风误诊及其临床病例分析培训班暨全国麻风皮肤性病学术年会(2010)论文集,2010.
  • 2王景权,陈家琨,沈建平,余美文.麻风病药物治疗的现状及进展[J].中国皮肤性病学杂志,2012,26(7):649-651. 被引量:14
  • 3沈建平.麻风病治疗不同观点或学派对麻风病治疗学科发展的影响[C].学科发展与科技创新-第五届学术交流理论研讨会论文集,2010.
  • 4张升伟,李芳英,王命蕙.夫妻俩瘤型麻风多次复发分析[C].中国麻风防治协会2011年年会论文集,2011.
  • 5张国成.WHO第八届麻风病专家委员会会议报告[R/OL].http://www.ynede.cn/,2012,6,25.
  • 6翁守能,崔春霞,费实,胡莉.贯彻落实科学发展观 努力推动皮防事业发展[J].现代医院,2009,9(5):122-124. 被引量:1

二级参考文献25

  • 1康玲,何冰男,王人众.当前医院思想政治工作难点与热点解析[J].现代医院管理,2007,5(2):31-33. 被引量:31
  • 2温家宝.十一届全国人大二次全体会议政府工作报告[N].人民日报,2009-3-6(1).
  • 3WHO. Global leprosy situation, 2010 [ J ]. Weekly epidemiological record, 2010, 85 (35) :337 -348.
  • 4Goto M, Nogami R, Hatano K, et al. Guideline for the treatment of Hansen' s disease in Japan (Second edition) [ J]. Nihon Hansenbyo Gakkai Zasshi ,2006,75 ( 3 ) : 191 - 226.
  • 5Yawalkar SJ. Leprosy for medical practition- ers and paramedical workers [ M ]. 6th ed.Switzerland: CIBA-GEIGY Limited,1996:83.
  • 6WHO. Enhanced Global Strategy for Further Reducing the Disease Burden Due to Leprosy [ S ]. Operational Guidelines ( Updated ) (2011 -2015) :36 -38.
  • 7Walker SL, Lockwood DN. Leprosy type 1 (reversal) reactions and their management [J]. Leprosy Review,2008,79(4) :372-386.
  • 8Van Brakel W, Cross H, Declercq E, et al. Review of leprosy research evidence (2002 -2009) and implications for current policy and practice [ J ]. Leprosy Review, 2010,81 (3) :228 -275.
  • 9Wang JQ. Take suicide prevention seriously in leprosaria[ J]. Lepr Rev,2011,82 ( 3 ) : 322 - 323.
  • 10Shen J, Liu M, Zhou M, et al. Causes of death among active leprosy patients in China [J]. Int J Dermatol,2011,50(1) :57 -60.

共引文献13

同被引文献13

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部